Evaluation of serious infections, including Mycobacterium tuberculosis, during treatment with biologic disease-modifying anti-rheumatic drugs: does line of therapy matter?

K Lauper, L Kearsley-Fleet, JB Galloway, KD Watson, KL Hyrich, M Lunt

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Evaluation of serious infections, including Mycobacterium tuberculosis, during treatment with biologic disease-modifying anti-rheumatic drugs: does line of therapy matter?'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology